

### **UnitedHealthcare® Medicare Advantage** Medical Policy

# Skin Substitutes Grafts/Cellular and Tissue-Based **Products (Injections and/or Applications)**

Policy Number: MMP105.17

Last Committee Approval Date: July 9, 2025

Effective Date: August 1, 2025

Table of Contents	Page
Coverage Rationale	1
Applicable Codes	1
Definitions	8
CMS Related Documents	8
Policy History/Revision Information	10
Instructions for Use	10

$\bigcirc$	Instructions for Use

Related	Medicare	e Advan	itage M	ledical F	olicy

Cosmetic and Reconstructive Procedures

### **Related Commercial Policy**

Skin and Soft Tissue Substitutes

## **Coverage Rationale**

### Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Medicare does not have a National Coverage Determination (NCD) for amniotic and placental derived product injections and/or applications for musculoskeletal indications, non-wound, Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist for all states and compliance with these policies is required where applicable. For specific LCDs/LCAs, refer to the table for Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound.

### Skin Substitutes Grafts/Cellular and Tissue-Based Products (CTP)

Medicare does not have an NCD for skin substitutes grafts/cellular and tissue-based products. LCDs/LCAs exist and compliance with these policies is required where applicable. For specific LCDs/LCAs, refer to the table for Skin Substitutes Grafts/Cellular and Tissue-Based Products (CTP).

For coverage guidelines for states/territories with no LCDs/LCAs or for indications not listed in the existing LCDs/LCAs other than breast reconstruction, refer to the UnitedHealthcare Commercial Medical Policy titled Skin and Soft Tissue Substitutes.

For coverage guidelines for skin and soft tissue substitutes used with a breast reconstructive procedure, refer to the UnitedHealthcare Medicare Advantage Medical Policy titled Cosmetic and Reconstructive Procedures.

# **Applicable Codes**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service; however, language may be included in the listing below to indicate if a code is non-covered. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

<b>HCPCS Code</b>	Description
A2001	InnovaMatrix AC, per sq cm
A2002	Mirragen Advanced Wound Matrix, per sq cm

Skin Substitutes Grafts/Cellular and Tissue-Based Products (Injections and/or Applications) UnitedHealthcare Medicare Advantage Medical Policy

Page 1 of 11 Effective 08/01/2025

<b>HCPCS Code</b>	Description		
A2004	XCelliStem, 1 mg		
A2005	Microlyte Matrix, per sq cm		
A2006	NovoSorb SynPath dermal matrix, per sq cm		
A2007	Restrata, per sq cm		
A2008	TheraGenesis, per sq cm		
A2009	Symphony, per sq cm		
A2010	Apis, per sq cm		
A2011	Supra SDRM, per sq cm		
A2012	SUPRATHEL, per sq cm		
A2013	Innovamatrix FS, per sq cm		
A2014	Omeza Collagen Matrix, per 100 mg		
A2015	Phoenix wound matrix, per sq cm		
A2016	PermeaDerm B, per sq cm		
A2017	PermeaDerm glove, each		
A2018	PermeaDerm C, per sq cm		
A2019	Kerecis Omega3 MariGen Shield, per sq cm		
A2021	NeoMatriX, per sq cm		
A2026	Restrata MiniMatrix, 5 mg		
A2027	MatriDerm, per sq cm		
A2028	MicroMatrix Flex, per mg		
A2029	MiroTract Wound Matrix sheet, per cc		
A2030	Miro3D fibers, per mg		
A2031	MiroDry Wound Matrix, per sq cm		
A2032	Myriad Matrix, per sq cm		
A2033	Myriad Morcells, 4 mg		
A2034	Foundation DRS Solo, per sq cm		
A2035	Corplex P or Theracor P or Allacor P, per mg		
A4100	Skin substitute, FDA-cleared as a device, not otherwise specified		
Q4100	Skin substitute, not otherwise specified		
Q4110	PriMatrix, per sq cm		
Q4111	GammaGraft, per sq cm		
Q4112	Cymetra, injectable, 1 cc		
Q4114	Integra flowable wound matrix, injectable, 1 cc		
Q4115	AlloSkin, per sq cm		
Q4117	HYALOMATRIX, per sq cm		
Q4118	MatriStem micromatrix, 1 mg		
Q4121	TheraSkin, per sq cm		
Q4122	DermACELL, DermACELL AWM or DermACELL AWM Porous, per sq cm		
Q4123	AlloSkin RT, per sq cm		
Q4125	Arthroflex, per sq cm		
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm		
Q4127	Talymed, per sq cm		
Q4130	Strattice TM, per sq cm		
Q4132	Grafix Core and GrafixPL Core, per sq cm		
Q4133	Grafix PRIME, GrafixPL PRIME, Stravix and StravixPL, per sq cm		

<b>HCPCS Code</b>	Description		
Q4134	HMatrix, per sq cm		
Q4135	Mediskin, per sq cm		
Q4136	E-Z Derm, per sq cm		
Q4137	AmnioExcel, AmnioExcel Plus or BioDExcel, per sq cm		
Q4138	BioDFence DryFlex, per sq cm		
Q4139	AmnioMatrix or BioDMatrix, injectable, 1 cc		
Q4140	BioDFence, per sq cm		
Q4141	AlloSkin AC, per sq cm		
Q4142	Xcm biologic tissue matrix, per sq cm		
Q4143	Repriza, per sq cm		
Q4145	EpiFix, injectable, 1 mg		
Q4146	Tensix, per sq cm		
Q4147	Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm		
Q4148	Neox Cord 1K, Neox Cord RT, or Clarix Cord 1K, per sq cm		
Q4149	Excellagen, 0.1 cc		
Q4150	AlloWrap DS or dry, per sq cm		
Q4151	AmnioBand or Guardian, per sq cm		
Q4152	DermaPure, per sq cm		
Q4153	Dermavest and Plurivest, per sq cm		
Q4154	Biovance, per sq cm		
Q4155	Neox Flo or Clarix Flo 1 mg		
Q4156	Neox 100 or Clarix 100, per sq cm		
Q4157	Revitalon, per sq cm		
Q4158	Kerecis Omega3, per sq cm		
Q4159	Affinity, per sq cm		
Q4160	Nushield, per sq cm		
Q4161	Bio-connekt wound matrix, per sq cm		
Q4162	WoundEx Flow, BioSkin Flow, 0.5 cc		
Q4163	WoundEx, BioSkin, per sq cm		
Q4164	Helicoll, per sq cm		
Q4165	Keramatrix or Kerasorb, per sq cm		
Q4166	Cytal, per sq cm		
Q4167	Truskin, per sq cm		
Q4168	Amnioband, 1 mg		
Q4169	Artacent wound, per sq cm		
Q4170	Cygnus, per sq cm		
Q4171	Interfyl, 1 mg		
Q4173	Palingen or palingen xplus, per sq cm		
Q4174	Palingen or promatrx, 0.36 mg per 0.25 cc		
Q4175	Miroderm, per sq cm		
Q4176	Neopatch, per sq cm		
Q4177	Floweramnioflo, 0.1 cc		
Q4178	Floweramniopatch, per sq cm		
Q4179	Flowerderm, per sq cm		
Q4180	Revita, per sq cm		

<b>HCPCS Code</b>	Description
Q4181	Amnio wound, per sq cm
Q4182	Transcyte, per sq cm
Q4183	Surgigraft, per sq cm
Q4184	Cellesta or Cellesta Duo, per sq cm
Q4185	Cellesta Flowable Amnion (25 mg per cc); per 0.5
Q4186	Epifix, per sq cm
Q4187	Epicord, per sq cm
Q4188	AmnioArmor, per sq cm
Q4189	Artacent AC, 1 mg
Q4190	Artacent AC, per sq cm
Q4191	Restorigin, per sq cm
Q4192	Restorigin, 1 cc
Q4193	Coll-e-Derm, per sq cm
Q4194	Novachor, per sq cm
Q4195	PuraPly, per sq cm
Q4196	PuraPly AM, per sq cm
Q4197	PuraPly XT, per sq cm
Q4198	Genesis Amniotic Membrane, per sq cm
Q4199	Cygnus matrix, per sq cm
Q4200	SkinTE, per sq cm
Q4201	Matrion, per sq cm
Q4202	Keroxx (2.5 g/cc), 1 cc
Q4203	Derma-Gide, per sq cm
Q4204	XWRAP, per sq cm
Q4205	Membrane graft or membrane wrap, per sq cm
Q4206	Fluid Flow or Fluid GF, 1 cc
Q4208	Novafix, per sq cm
Q4209	SurGraft, per sq cm
Q4211	Amnion Bio or AxoBioMembrane, per sq cm
Q4212	AlloGen, per cc
Q4213	Ascent, 0.5 mg
Q4214	Cellesta Cord, per sq cm
Q4215	Axolotl Ambient or Axolotl Cryo, 0.1 mg
Q4216	Artacent Cord, per sq cm
Q4217	WoundFix, BioWound, WoundFix Plus, BioWound Plus, WoundFix Xplus or BioWound Xplus, per sq cm
Q4218	SurgiCORD, per sq cm
Q4219	SurgiGRAFT-DUAL, per sq cm
Q4220	BellaCell HD or Surederm, per sq cm
Q4221	Amnio Wrap2, per sq cm
Q4222	ProgenaMatrix, per sq cm
Q4224	Human Health Factor 10 Amniotic Patch (HHF10-P), per sq cm
Q4225	AmnioBind or DermaBind TL, per sq cm
Q4226	MyOwn Skin, includes harvesting and preparation procedures, per sq cm
Q4227	AmnioCore, per sq cm

HCPCS Code	Description		
Q4229	Cogenex Amniotic Membrane, per sq cm		
Q4230	Cogenex flowable amnion, per 0.5 cc		
Q4231	Corplex p, per cc (Deleted 03/31/2025, see A2035)		
Q4232	Corplex, per aq cm		
Q4233	Surfactor or nudyn, per 0.5 cc		
Q4234	Xcellerate, per sq cm		
Q4235	AMNIOREPAIR or AltiPly, per sq cm		
Q4236	carePATCH, per sq cm		
Q4237	Cryo-Cord, per sq cm		
Q4238	Derm-Maxx, per sq cm		
Q4239	Amnio-Maxx or Amnio-Maxx Lite		
Q4240	Corecyte, for topical use only, per 0.5 cc		
Q4241	Polycyte, for topical use only, per 0.5 cc		
Q4242	Amniocyte plus, per 0.5 cc		
Q4245	Amniotext, per cc		
Q4246	Coretext or protext, per cc		
Q4247	Amniotext patch, per sq cm		
Q4248	Dermacyte Amniotic Membrane Allograft, per sq cm		
Q4249	AMNIPLY, for topical use only, per sq cm		
Q4250	AmnioAmp-MP, per sq cm		
Q4251	Vim, per sq cm		
Q4252	Vendaje, per sq cm		
Q4253	Zenith amniotic membrane, per sq cm		
Q4254	Novafix DL, per sq cm		
Q4255	REGUaRD, for topical use only, per sq cm		
Q4256	MLG-Complete, per sq cm		
Q4257	Relese, per sq cm		
Q4258	Enverse, per sq cm		
Q4259	Celera Dual Layer or Celera Dual Membrane, per sq cm		
Q4260	Signature APatch, per sq cm		
Q4261	TAG, per sq cm		
Q4262	Dual Layer impax Membrane, per sq cm		
Q4263	Surgraft TL, per sqcm		
Q4264	Cocoon membrane, per sq cm		
Q4265	NeoStim TL, per sq cm		
Q4266	NeoStim Membrane, per sq cm		
Q4267	NeoStim DL, per sq cm		
Q4268	SurGraft FT, per sq cm		
Q4269	SurGraft XT, per sq cm		
Q4270	Complete SL, per sq cm		
Q4271	Complete FT, per sq cm		
Q4272	Esano A, per sq cm		
Q4273	Esano AAA, per sq cm		
Q4274	Esano AC, per sq cm		
Q4275	Esano ACA, per sq cm		

<b>HCPCS Code</b>	Description		
Q4276	ORION, per sq cm		
Q4278	EPIEFFECT, per sq cm		
Q4279	Vendaje AC, per sq cm		
Q4280	Xcell Amnio Matrix, per sq cm		
Q4281	Barrera SL or Barrera DL, per sq cm		
Q4282	Cygnus Dual, per sq cm		
Q4283	Biovance Tri-Layer or Biovance 3L, per sq cm		
Q4284	DermaBind SL, per sq cm		
Q4287	DermaBind DL, per sq cm		
Q4288	DermaBind CH, per sq cm		
Q4289	RevoShield+ Amniotic Barrier, per sq cm		
Q4290	Membrane Wrap-Hydro <sup>™</sup> , per sq cm		
Q4291	Lamellas XT, per sq cm		
Q4292	Lamellas, per sq cm		
Q4293	Acesso DL, per sq cm		
Q4294	Amnio Quad-Core, per sq cm		
Q4295	Amnio Tri-Core Amniotic, per sq cm		
Q4296	Rebound Matrix, per sq cm		
Q4297	Emerge Matrix, per sq cm		
Q4298	AmniCore Pro, per sq cm		
Q4299	AmniCore Pro+, per sq cm		
Q4300	Acesso TL, per sq cm		
Q4301	Activate Matrix, per sq cm		
Q4302	Complete ACA, per sq cm		
Q4303	Complete AA, per sq cm		
Q4304	GRAFIX PLUS, per sq cm		
Q4305	American Amnion AC Tri-Layer, per sq cm		
Q4306	American Amnion AC, per sq cm		
Q4307	American Amnion, per sq cm		
Q4308	Sanopellis, per sq cm		
Q4309	VIA Matrix, per sq cm		
Q4310	Procenta, per 100 mg		
Q4311	Acesso, per sq cm		
Q4312	Acesso AC, per sq cm		
Q4313	DermaBind FM, per sq cm		
Q4314	Reeva FT, per sq cm		
Q4315	RegeneLink Amniotic Membrane Allograft, per sq cm		
Q4316	AmchoPlast, per sq cm		
Q4317	VitoGraft, per sq cm		
Q4318	E-Graft, per sq cm		
Q4319	SanoGraft, per sq cm		
Q4320	PelloGraft, per sq cm		
Q4321	RenoGraft, per sq cm		
Q4322	CaregraFT, per sq cm		
Q4323	alloPLY, per sq cm		

<b>HCPCS Code</b>	Description		
Q4324	AmnioTX, per sq cm		
Q4325	ACApatch, per sq cm		
Q4326	WoundPlus, per sq cm		
Q4327	DuoAmnion, per sq cm		
Q4328	MOST, per sq cm		
Q4329	Singlay, per sq cm		
Q4330	TOTAL, per sq cm		
Q4331	Axolotl Graft, per sq cm		
Q4332	Axolotl DualGraft, per sq cm		
Q4333	ArdeoGraft, per sq cm		
Q4334	AmnioPlast 1, per sq cm		
Q4335	AmnioPlast 2, per sq cm		
Q4336	Artacent C, per sq cm		
Q4337	Artacent Trident, per sq cm		
Q4338	Artacent Velos, per sq cm		
Q4339	Artacent Vericlen, per sq cm		
Q4340	SimpliGraft, per sq cm		
Q4341	SimpliMax, per sq cm		
Q4342	TheraMend, per sq cm		
Q4343	Dermacyte AC Matrix Amniotic Membrane Allograft, per sq cm		
Q4344	Tri-Membrane Wrap, per sq cm		
Q4345	Matrix HD Allograft Dermis, per sq cm		
Q4346	Shelter DM Matrix, per sq cm		
Q4347	Rampart DL Matrix, per sq cm		
Q4348	Sentry SL Matrix, per sq cm		
Q4349	Mantle DL Matrix, per sq cm		
Q4350	Palisade DM Matrix, per sq cm		
Q4351	Enclose TL Matrix, per sq cm		
Q4352	Overlay SL Matrix, per sq cm		
Q4353	Xceed TL Matrix, per sq cm		
Q4354	PalinGen Dual-Layer Membrane, per sq cm		
Q4355	Abiomend Xplus Membrane and Abiomend Xplus Hydromembrane, per sq cm		
Q4356	Abiomend Membrane and Abiomend Hydromembrane, per sq cm		
Q4357	XWRAP Plus, per sq cm		
Q4358	XWRAP Dual, per sq cm		
Q4359	ChoriPly, per sq cm		
Q4360	AmchoPlast FD, per sq cm		
Q4361	EPIXPRESS, per sq cm		
Q4362	CYGNUS Disk, per sq cm		
Q4363	Amnio Burgeon Membrane and Hydromembrane, per sq cm		
Q4364	Amnio Burgeon Xplus Membrane and Xplus Hydromembrane, per sq cm		
Q4365	Amnio Burgeon Dual-Layer Membrane, per sq cm		
Q4366	Dual Layer Amnio Burgeon X-Membrane, per sq cm		
Q4367	AmnioCore SL, per sq cm		

### **Definitions**

**Cellular and/or Tissue-Based Products (CTPs)**: CTPs accurately describes these products inclusive of both current and future technology. This terminology has been adopted and accepted by the wound care community, contractors, and other government agencies. The American Society for Testing and Materials (ASTM) updated its standard guide to define CTP nomenclature, and they have also included synthetic products within the definition of a CTP. <u>A59518 - Response to Comments: Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.</u>

# Centers for Medicare and Medicaid Services (CMS) Related Documents

After checking the table below and searching the <u>Medicare Coverage Database</u>, if no NCD, LCD, or LCA is found, refer to the criteria as noted in the <u>Coverage Rationale</u> section above.

NCD	LCD	LCA	Contractor Type	<b>Contractor Name</b>	
Skin Substitutes Grafts/Cellular and Tissue- Based Products (CTP)					
N/A	L36690 Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities	A56696 Billing and Coding: Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities	Part A and B MAC	CGS	
N/A	L36377 Application of Skin Substitute Grafts for Treatment of DFU and VLU of Lower Extremities	A57680 Billing and Coding: Application of Skin Substitute Grafts for Treatment of DFU and VLU of Lower Extremities	Part A and B MAC	First Coast	
	L35041 Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non- Healing Wounds.	A54117 Billing and Coding: Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non- Healing Wounds	Part A and B MAC	Novitas**	
Amniotic and Plac Wound	ental Derived Product Inject	tions and/or Applications fo	r Musculoskeletal Ir	ndications, Non-	
N/A	L39575 Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	A59374 Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	Part A and B MAC	CGS	
	L39877 Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	A59764 Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	Part A and B MAC	First Coast	
	L39139 Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	A58893 Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	Part A and B MAC	NGS	

NCD	LCD	LCA	•	Contractor Name
Wound	ental Derived Product Injec	ctions and/or Applications fo	or Musculoskeletal li	ndications, Non-
N/A	L39116 Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	A58865 Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	Part A and B MAC	Noridian
	L39118 Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	A58867 Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	Part A and B MAC	Noridian
	L39879 Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	A59766 Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	Part A and B MAC	Novitas**
	L39128 Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	A58883 Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	Part A and B MAC	Palmetto**
	L39624 Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	A59434 Billing and Coding: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	Part A and B MAC	WPS*

Medicare Administrative Contractor (MAC) With Corresponding States/Territories	
MAC Name (Abbreviation)	States/Territories
CGS Administrators, LLC (CGS)	KY, OH
First Coast Service Options, Inc. (First Coast)	FL, PR, VI
National Government Services, Inc. (NGS)	CT, IL, ME, MA, MN, NH, NY, RI, VT, WI
Noridian Healthcare Solutions, LLC (Noridian)	AS, AK, AZ, CA, GU, HI, ID, MT, NV, ND, Northern Mariana Islands, OR, SD, UT, WA, WY
Novitas Solutions, Inc. (Novitas)	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX, VA**
Palmetto GBA (Palmetto)	AL, GA, NC, SC, TN, VA**, WV
Wisconsin Physicians Service Insurance Corporation (WPS)*	IA, IN, KS, MI, MO, NE

#### **Notes**

<sup>\*</sup>Wisconsin Physicians Service Insurance Corporation: Contract Number 05901 applies only to WPS Legacy Mutual of Omaha MAC A Providers.

<sup>\*\*</sup>For the state of Virginia: Part B services for the city of Alexandria and the counties of Arlington and Fairfax are excluded for the Palmetto GBA jurisdiction and included within the Novitas Solutions, Inc. jurisdiction.

# **Policy History/Revision Information**

Date	Summary of Changes
08/01/2025	<b>Applicable Codes</b> • Added HCPCS codes A2030, A2031, A2032, A2033, A2034, Q4354, Q4355, Q4356, Q4357,
	Q4358, Q4359, Q4360, Q4361, Q4362, Q4363, Q4364, Q4365, Q4366, and Q4367
	Centers for Medicare and Medicaid Services (CMS) Related Documents
	<ul> <li>Updated list of documents available in the Medicare Coverage Database to reflect the most current information</li> </ul>
	Supporting Information
	Archived previous policy version MMP105.16

### **Instructions for Use**

The Medicare Advantage Policy documents are generally used to support UnitedHealthcare coverage decisions. It is expected providers retain or have access to appropriate documentation when requested to support coverage. This document may be used as a guide to help determine applicable:

- Medical necessity coverage guidelines; including documentation requirements, and/or
- Medicare coding or billing requirements.

Medicare Advantage Policies are applicable to UnitedHealthcare Medicare Advantage Plans offered by UnitedHealthcare and its affiliates. This Policy is provided for informational purposes and does not constitute medical advice. It is intended to serve only as a general reference and is not intended to address every aspect of a clinical situation. Physicians and patients should not rely on this information in making health care decisions. Physicians and patients must exercise their independent clinical discretion and judgment in determining care. Treating physicians and healthcare providers are solely responsible for determining what care to provide to their patients. Members should always consult their physician before making any decisions about medical care.

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The member specific benefit plan document identifies which services are covered, which are excluded, and which are subject to limitations. In the event of a conflict, the member specific benefit plan document supersedes this policy. For more information on a specific member's benefit coverage, please call the customer service number on the back of the member ID card or refer to the Administrative Guide.

Medicare Advantage Policies are developed as needed, are regularly reviewed, and updated, and are subject to change. They represent a portion of the resources used to support UnitedHealthcare coverage decision making. UnitedHealthcare may modify these Policies at any time by publishing a new version on this website. Medicare source materials used to develop these policies may include, but are not limited to, CMS statutes, regulations, National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and manuals. This document is not a replacement for the Medicare source materials that outline Medicare coverage requirements. The information presented in this Policy is believed to be accurate and current as of the date of publication. Where there is a conflict between this document and Medicare source materials, the Medicare source materials apply. Medicare Advantage Policies are the property of UnitedHealthcare. Unauthorized copying, use, and distribution of this information are strictly prohibited.

UnitedHealthcare follows Medicare coverage guidelines found in statutes, regulations, NCDs, and LCDs to determine coverage. The clinical coverage criteria governing certain items or services referenced in this Medical Policy have not been fully established in applicable Medicare guidelines because there is an absence of any applicable Medicare statutes, regulations, NCDs, or LCDs setting forth coverage criteria and/or the applicable NCDs or LCDs include flexibility that explicitly allows for coverage in circumstances beyond the specific indications that are listed in an NCD or LCD. As a result, in these circumstances, UnitedHealthcare applies internal coverage criteria as referenced in this Medical Policy. The internal coverage criteria in this Medical Policy was developed through an evaluation of the current relevant clinical evidence in acceptable clinical literature and/or widely used treatment guidelines. UnitedHealthcare evaluated the evidence to determine whether it was of sufficient quality to support a finding that the items or services discussed in the policy might, under certain circumstances, be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Providers are responsible for submission of accurate claims. Medicare Advantage Policies are intended to ensure that coverage decisions are made accurately. UnitedHealthcare Medicare Advantage Policies use Current Procedural Terminology (CPT®), Centers for Medicare and Medicaid Services (CMS), or other coding guidelines. References to CPT® or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee claims payment.

For members in UnitedHealthcare Medicare Advantage plans where a delegate manages utilization management and prior authorization requirements, the delegate's requirements need to be followed.